NCT05481879View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
DRUG

DYNE-101

Administered by IV infusion

DRUG

Placebo

Administered by IV infusion

Trial Locations (9)

1023

RECRUITING

NZCR Auckland, Auckland

20162

RECRUITING

Centro Clinico Nemo, Milan

75013

RECRUITING

Institut de Myologie, Paris

80336

RECRUITING

Ludwig Maximilians University, Munich - Friedrich Baur Institut, Munich

00168

RECRUITING

Fondazione Policlinico Universitario A Gemelli-Rome, Rome

Unknown

RECRUITING

Radboud Medical Center, Nijmegen

RECRUITING

John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne

NW1 2BU

RECRUITING

University College London Hospitals, London

M6 8HD

RECRUITING

Salford Royal Hospital, Salford

Sponsors

Lead Sponsor

Dyne Therapeutics
All Listed Sponsors
lead

Dyne Therapeutics

INDUSTRY

NCT05481879 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | Biotech Hunter | Biotech Hunter